Reimbursed with a limitationOriginator productATC L01EL03

Brukinsa

Brukinsa is an originator product from BeOne Medicines I GmbH and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 4'680.80 to CHF 4'680.80 depending on the pack; the patient co-payment is 10 per cent plus the deductible.

Core data

Authorisation holder
BeOne Medicines I GmbH
ATC code
L01EL03
IT group
07.16.10 Cytostatica
Active substances
Zanubrutinibum
Preparation type
Originator product
On the SL since
01/05/2022
Last price change
01/10/2025
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Brukinsa Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Kaps 80 mgFl 120 StkCHF 4'288.85CHF 4'680.8001/05/2022A8720598340105

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingIndication 21365.XXValid from 01/10/2023

Zanubrutinib wird nicht bei Patienten vergütet, bei denen unter BTK-lnhibitoren eine Krankheitsprogression auftrat. Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.

FOPH wordingIndication 21365.01Valid from 01/10/2025

2L+ chronisch lymphatische Leukämie (CLL, Monotherapie)
Als Monotherapie zur Behandlung erwachsener Patienten mit CLL, die mindestens eine Vortherapie erhalten haben.
Folgender Code ist an den Krankenversicherer zu übermitteln: 21365.01

FOPH wordingIndication 21365.02Valid from 01/10/2025

Morbus Waldenström (MW, Monotherapie)
Als Monotherapie ab der ersten Linie zur Behandlung symptomatischer erwachsener Patienten mit MW, die für eine Rituximab basierte Chemo Immuntherapie (DRC, BR, BDR, VR) nicht in Frage kommen.
Folgender Code ist an den Krankenversicherer zu übermitteln: 21365.02

FAQ

Is Brukinsa covered by Swiss health insurance?

Yes, but only under conditions. Brukinsa is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Brukinsa cost in Switzerland?

The public price is the maximum price set by the FOPH and for Brukinsa ranges from CHF 4'680.80 to CHF 4'680.80 per pack. The ex-factory price ranges from CHF 4'288.85 to CHF 4'288.85. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com